Cel-Sci (CVM) vs Lite Strategy (LITS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lite Strategy (LITS) has outperformed Cel-Sci (CVM) over the past year, losing 51.2% versus a loss of 80.6%. Over five years, LITS leads with a -97.9% price change compared with -99.4% for CVM. Lite Strategy is the larger company by market cap ($37.1 million vs $34.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | LITS |
|---|---|---|
| Share price | $1.95 | $1.22 |
| Market cap | $34.30M | $37.10M |
| 1-day change | -8.45% | -3.94% |
| YTD return | -62.93% | -7.58% |
| 1-year return | -80.56% | -51.20% |
| 5-year return | -99.38% | -97.90% |
| EPS (TTM) | $-1.69 | $-2.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.24 | $2.97 |
| 52-week low | $0.89 | $0.69 |
| Distance from 52-week high | -80.96% | -58.92% |
| Analyst consensus | none | — |
| Avg. price target upside | +541.03% | — |
| Average volume | 243.94K | 462.76K |
| Shares outstanding | 17.59M | 30.41M |
| Employees | — | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LITS has outperformed CVM by 29.4 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Lite Strategy
LITS stock →Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CVM vs LITS FAQ
Which is bigger, Cel-Sci or Lite Strategy?
Lite Strategy (LITS) is larger, with a market capitalization of $37.10M compared with $34.30M for Cel-Sci (CVM).
Which stock has performed better over the past year, CVM or LITS?
LITS returned -51.20% over the past 12 months, compared with -80.56% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and Lite Strategy in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cel-Sci and Biotechnology: Pharmaceutical Preparations for Lite Strategy.